Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBMUWZ)

Drug Name
Emtricitabine Drug Info
Synonyms
Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
Indication
Disease Entry ICD 11 Status REF
Hepatitis virus infection 1E50-1E51 Approved [1]
Human immunodeficiency virus infection 1C62 Approved [1]
Hepatitis B virus infection 1E51.0 Phase 3 [2]
Therapeutic Class
Anti-HIV Agents
Cross-matching ID
PubChem CID
60877
ChEBI ID
CHEBI:31536
CAS Number
CAS 143491-57-0
TTD Drug ID
DMBMUWZ
VARIDT Drug ID
DR00672
ACDINA Drug ID
D00228

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [7]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [8]
Zalcitabine DMH7MUV Human immunodeficiency virus infection 1C62 Approved [9]
Tenofovir DM1IS6U Chronic hepatitis B virus infection Approved [7]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [10]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [11]
Delavirdine DM3NF5G Human immunodeficiency virus infection 1C62 Approved [10]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [10]
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [12]
Etravirine DMGV8QU Human immunodeficiency virus-1 infection 1C62 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aciclovir DMYLOVR Genital herpes 1A94 Approved [14]
Metformin DM89QE1 Colorectal carcinoma Approved [15]
Ganciclovir DM1MBYQ Cytomegalovirus infection 1D82 Approved [14]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [14]
Chloroquine DMSI5CB Malaria 1F40-1F45 Approved [16]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [14]
Topotecan DMP6G8T Central nervous system neoplasm Approved [14]
Cephalexin DMD5JU8 Acute otitis media AB00 Approved [17]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [18]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By E3 ubiquitin-protein ligase parkin (PRKN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tubocurarine DMBZIVP Anaesthesia 9A78.6 Approved [20]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [21]
Ethanol DMDRQZU Chronic pain MG30 Approved [22]
Trifluoperazine DMKBYWI Anxiety Approved [23]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [24]
Methamphetamine DMPM4SK Anxiety Approved [25]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [26]
Arsenic DMTL2Y1 N. A. N. A. Approved [27]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [28]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [29]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [30]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [31]
Diazepam DM08E9O Alcohol withdrawal Approved [32]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [33]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [34]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [35]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [36]
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Deoxycytidine kinase (DCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [43]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [44]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [45]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [46]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [28]
DEOXYCYTIDINE DMYE5LJ Acute myeloid leukaemia 2A60 Approved [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [4]
Deoxycytidine kinase (DCK) OTW8HLZC DCK_HUMAN Protein Interaction/Cellular Processes [5]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Gene/Protein Processing [6]

References

1 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
2 Clinical pipeline report, company report or official report of Gilead (2011).
3 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
4 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
5 Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. doi: 10.1021/jm0700215. Epub 2007 May 27.
6 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
7 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
8 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
9 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
12 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
13 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
14 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
15 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
16 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
17 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
18 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
19 FDA Drug Development and Drug Interactions
20 Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
21 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
22 Silibinin inhibits ethanol- or acetaldehyde-induced ferroptosis in liver cell lines. Toxicol In Vitro. 2022 Aug;82:105388. doi: 10.1016/j.tiv.2022.105388. Epub 2022 May 18.
23 Rescue of Pink1 Deficiency by Stress-Dependent Activation of Autophagy. Cell Chem Biol. 2017 Apr 20;24(4):471-480.e4. doi: 10.1016/j.chembiol.2017.03.005. Epub 2017 Mar 30.
24 Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci. 2006 Sep;24(5):1366-72. doi: 10.1111/j.1460-9568.2006.04998.x.
25 Involvement of C/EBP-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett. 2019 Sep 15;312:11-21. doi: 10.1016/j.toxlet.2019.05.003. Epub 2019 May 3.
26 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
27 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
28 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
29 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
30 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
31 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
32 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
33 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
34 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
35 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
36 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
37 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
38 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
39 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
40 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
41 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
42 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
43 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
44 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
45 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
46 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.